The latest news on cancer diagnostics, liquid biopsy, and cancer risk testing.
The agreement enables NeuMoDx to bring sample-to-result HPV screening to customers in Europe, where its systems are distributed by Qiagen.
The firm said that the second tranche is part of the financing provided by Ampersand Capital for the $23.5 million acquisition of Cancer Genetics' biopharma business earlier this year.
The method uses DESI-MS imaging to analyze fine-needle aspiration biopsies and could help evaluate cases where traditional cytology is inconclusive.
The partners said that the first project will focus on the discovery of breath biomarkers for chronic liver diseases and liver-related cancers.
The company has collected initial evidence for an algorithmic method to predict immunotherapy response, and is studying its technology in treatment monitoring.
